pubmed-article:8018462 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:8018462 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
pubmed-article:8018462 | lifeskim:mentions | umls-concept:C1708335 | lld:lifeskim |
pubmed-article:8018462 | lifeskim:mentions | umls-concept:C0016377 | lld:lifeskim |
pubmed-article:8018462 | lifeskim:mentions | umls-concept:C0743223 | lld:lifeskim |
pubmed-article:8018462 | lifeskim:mentions | umls-concept:C0205171 | lld:lifeskim |
pubmed-article:8018462 | lifeskim:mentions | umls-concept:C0599473 | lld:lifeskim |
pubmed-article:8018462 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:8018462 | pubmed:dateCreated | 1994-8-4 | lld:pubmed |
pubmed-article:8018462 | pubmed:abstractText | Plasma concentrations of the enantiomers of flurbiprofen were measured following oral administration of (S)-flurbiprofen 50 mg and (R)-flurbiprofen 50 mg and 100 mg to sixteen healthy subjects. Chiral inversion did not occur to a measurable extent. Significantly higher values of AUC (55.2 +/- 17.0 vs 44.6 +/- 11.2 micrograms ml-1h) elimination half-life (5.6 +/- 1.4 vs 4.0 +/- 1.0 h) and mean residence time (7.5 +/- 1.6 vs 5.7 +/- 1.2 h) were observed after 50 mg (S)-flurbiprofen as compared with 50 mg (R)-flurbiprofen. With the exception of Cmax and AUC values pharmacokinetic data for the 50 mg and the 100 mg dose of (R)-flurbiprofen did not differ significantly. The data are of clinical relevance if (R)-flurbiprofen also has analgesic activity in humans and is to be developed as an analgesic. | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:language | eng | lld:pubmed |
pubmed-article:8018462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:8018462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:8018462 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:8018462 | pubmed:month | Apr | lld:pubmed |
pubmed-article:8018462 | pubmed:issn | 0306-5251 | lld:pubmed |
pubmed-article:8018462 | pubmed:author | pubmed-author:BruneKK | lld:pubmed |
pubmed-article:8018462 | pubmed:author | pubmed-author:MenzelSS | lld:pubmed |
pubmed-article:8018462 | pubmed:author | pubmed-author:KobalGG | lld:pubmed |
pubmed-article:8018462 | pubmed:author | pubmed-author:GeisslingerGG | lld:pubmed |
pubmed-article:8018462 | pubmed:author | pubmed-author:LötschJJ | lld:pubmed |
pubmed-article:8018462 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:8018462 | pubmed:volume | 37 | lld:pubmed |
pubmed-article:8018462 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:8018462 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:8018462 | pubmed:pagination | 392-4 | lld:pubmed |
pubmed-article:8018462 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:meshHeading | pubmed-meshheading:8018462-... | lld:pubmed |
pubmed-article:8018462 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:8018462 | pubmed:articleTitle | Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. | lld:pubmed |
pubmed-article:8018462 | pubmed:affiliation | Department of Experimental and Clinical Pharmacology and Toxicology, University of Erlangen-Nürnberg, Germany. | lld:pubmed |
pubmed-article:8018462 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:8018462 | pubmed:publicationType | Clinical Trial | lld:pubmed |
pubmed-article:8018462 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:8018462 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
pubmed-article:8018462 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018462 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8018462 | lld:pubmed |